Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: Dr Holtzman, in his Editorial1 accompanying our study of expanded newborn screening
for biochemical genetic disorders,2 stated
that adoption of new screening technology was brought about by pressure from
medico-legal proceedings initiated by parents. He did not mention, however,
the strong and dedicated advocacy from metabolic and genetic physicians, individually
and through organizations such as the Society of Inherited Metabolic disorders,
who recognized the potential benefit to patients and their families.
Waisbren SE, Levy HL. Expanded Screening of Newborns for Genetic Disorders. JAMA. 2004;291(7):820–821. doi:10.1001/jama.291.7.820-c